Real world efficacy and safety of teriflunomide in patients with relapsing-remitting multiple sclerosis
dc.contributor.author | Boz, Cavit | |
dc.contributor.author | Özakbaş, Serkan | |
dc.contributor.author | Terzi, Murat | |
dc.contributor.author | Türkoğlu, Recai | |
dc.contributor.author | Akman, Gülşen | |
dc.contributor.author | Efendi, Hüsnü | |
dc.contributor.author | Akçalı, Aylin | |
dc.contributor.author | Tuncer, Alaettin | |
dc.contributor.author | Yüceyar, Nur | |
dc.contributor.author | Soysal, Aysun | |
dc.contributor.author | Köseoğlu, M. | |
dc.contributor.author | Balcı, Belgin Petek | |
dc.contributor.author | Sevim, Serhan | |
dc.contributor.author | Altıntaş, Ayşe | |
dc.contributor.author | Çilingir, Vedat | |
dc.contributor.author | Demirkıran, Meltem | |
dc.contributor.author | Kızılay, Ferah | |
dc.contributor.author | Altunrende, Burcu | |
dc.contributor.buuauthor | Turan, Ömer Faruk | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı. | tr_TR |
dc.date.accessioned | 2023-08-08T13:31:23Z | |
dc.date.available | 2023-08-08T13:31:23Z | |
dc.date.issued | 2017-10 | |
dc.description | Bu çalışma, 25-28, Ekim 2017 tarihlerinde Paris[Fransa]’ de düzenlenen 7. Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) Kongresi‘nde bildiri olarak sunulmuştur. | tr_TR |
dc.description.sponsorship | Merck & Company | en_US |
dc.description.sponsorship | Novartis | en_US |
dc.description.sponsorship | Bayer AG | en_US |
dc.description.sponsorship | Teva Pharmaceutical Industries | en_US |
dc.description.sponsorship | European Comm Treatment & Res Multiple Sclerosis | en_US |
dc.description.sponsorship | Americas Comm Treatment & Res Multiple Sclerosis | en_US |
dc.identifier.citation | Boz, C. vd. (2017). ''Real world efficacy and safety of teriflunomide in patients with relapsing-remitting multiple sclerosis''. Multiple Sclerosis Journal, 23(Supplement 3), 327-328. | en_US |
dc.identifier.endpage | 328 | tr_TR |
dc.identifier.issn | 1352-4585 | |
dc.identifier.issn | 1477-0970 | |
dc.identifier.issue | Suplement 3 | en_US |
dc.identifier.startpage | 327 | tr_TR |
dc.identifier.uri | https://journals.sagepub.com/toc/msja/23/3_suppl | |
dc.identifier.uri | http://hdl.handle.net/11452/33415 | |
dc.identifier.volume | 23 | tr_TR |
dc.identifier.wos | 000413730202068 | tr_TR |
dc.indexed.wos | SCIE | en_US |
dc.indexed.wos | CPCIS | en_US |
dc.language.iso | en | en_US |
dc.publisher | Sage Puplications | en_US |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.relation.collaboration | Sanayi | tr_TR |
dc.relation.journal | Multiple Sclerosis Journal | en_US |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Neurosciences & neurology | en_US |
dc.subject.wos | Clinical neurology | en_US |
dc.subject.wos | Neurosciences | en_US |
dc.title | Real world efficacy and safety of teriflunomide in patients with relapsing-remitting multiple sclerosis | en_US |
dc.type | Meeting Abstract | |
dc.wos.quartile | Q1 | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: